Category Archives: Transactions

Orbit Financial Capital acted as the exclusive sell-side advisor to Pan Health for raising USD 50 Million from Motilal Oswal Private Equity.

MOPE picked up a minority stake in Pan Health by investing ~USD 50 Mn (INR 400Crs) from its India Business Excellence Fund IV (IBEF – IV), making it one of the largest investments from their current Fund.

MO Alternate Investment Advisors (MO Alts) manages both Private Equity and Real Estate funds with ~USD 1.7 Bn in AUM. The private equity vertical in the last 16 years has made over 40 investments and has exited 15 investments, delivering a gross
MOIC (multiple on invested capital) of 5.3x and gross IRR of 26.7%.

About Pan Health: The Health and Hygiene business segment of the PAN Group is headquartered in Rajkot, Gujarat with operations spread across 4 entities. The Company sells baby diapers under Little Angel brand, adult incontinence products under Liberty
brand, and sanitary napkins and feminine hygiene products under Everteen brand. It also sells personal care products under brands named Neud, Mansure and Naturesure.

The funds will be utilized to build the brands, expand the distribution infrastructure, and create a robust organization to accelerate their growth story.

We are glad to announce that Orbit Financial Capital acted as the exclusive financial advisor to Sunways India in securing USD 15 million from InvAscent.

Orbit Financial Capital continues to successfully execute PE/M&A deals by providing transaction advisory services that are aligned with the client’s strategic goals in addition to efficiently raising debt for its esteemed clients.

The transaction advisory team focuses on identifying strategic fits for our clients and enabling them to grow their business through the inorganic route by making acquisitions that provide access to newer markets, better technologies, and innovative products and result in creating shareholder value. By capitalizing on our core competencies and deep domain knowledge in equity syndication, we assist our clients to raise equity capital from varied sources such as Venture capitalists, Private Equity Firms, HNIs, and angel investor space. The team has closed many transactions with leading companies globally. Read more about Orbit Financial Capital – https://orbitfinancial.in/

Domestic Ophthalmic player, Sunways has raised USD 15 million from InvAscent for capacity addition, international expansion and acquisitions. InvAscent is the investment advisor to a family of funds that operate under the name “India Life Sciences Fund” or ILSF. It has so far raised USD 500 Mn from global investors since its founding in 2007 and deployed the same in 30+ companies across Pharma, Healthcare Delivery, Medical Devices and Animal Health sectors. The investment team at InvAscent has deep domain expertise and a track record of value creation in the Life Sciences space.

Founded in the 1950s by the Shroff family, Mumbai-headquartered Sunways is a leading manufacturer and marketer of ophthalmic formulations. Having a strong foundation built over 70 years and 3 generations, Sunways is well established to progress into the next phase of sprinted growth domestically and in the international markets. This growth would be supported by organic and inorganic expansion. The Company has a strong presence across India and also exports to 10+ countries.

Orbit Financial Capital acted as the exclusive sell-side advisor to Selvax for securing an Industry Partnership with Gufic Bioscience Ltd.

Gufic Bioscience Ltd picked up a minority stake in Selvax Pty Ltd and undertake mutually agreed development activities in return for the exclusive commercial rights for Selvax immunotherapy in India along with an equal share of future revenues in Europe.

Incorporated in the year 2000, Gufic Biosciences Limited is engaged in manufacture and marketing of pharmaceutical formulations in various dosage forms such as injectables, syrups, ointments, lotions etc.

About Selvax: Founded in 2014, Selvax Pty Ltd is a bio-technology company based in Perth, West Australia, which is developing a novel immunology based treatment for large solid tumours. Their “self-vaccine” technology has achieved cancer clearance rates in the range of 30% – 100% in repeated small animal studies for a range of solid tumours.